Generic SupplierYour reliable supplier of generic medications
$0.00 (0 items)Checkout

Categories list

Social bookmarks:

Our billing is certified by:

Secure shopping certificates

Special Offer!

Generic Montelukast - Singulair

Search by letter:

ABCDEFGHIJKLMNOPQRSTUVWXYZ
 
 
 
Singulair $0.87
Per pill
SingulairMontelukast 4/5/10mg
Buy now!
 
quicksearch
quicksearch

Thank you for your great service. I have received it and it is everything you said it would be. I will recommend your site to my friends. Thank you once again.


Moneyback Guarantee
bookmark Bookmark this site
Subscribe to the News

Latest News

  • Can Montelukast Reduce the Frequency of URTI in Children? - Medscape

    Can Montelukast Reduce the Frequency of URTI in Children?MedscapeMontelukast selectively inhibits leukotriene receptors, thereby limiting the ability of leukotrienes to trigger inflammation.

  • Major Pharmaceuticals Prepare Themselves for Patent Expirations in 2012 - MarketWatch (press release)

    Major Pharmaceuticals Prepare Themselves for Patent Expirations in 2012MarketWatch (press release)Merck's worldwide sales of SINGULAIR (montelukast sodium), a once-a-day oral medicine for the chronic treatment of asthma and the relief of symptoms of allergic rhinitis, grew 1 percent from the first quarter of 2011 to $1.

  • Asthma drugs: What every parent should know - Philadelphia Inquirer

    Philadelphia InquirerAsthma drugs: What every parent should knowPhiladelphia InquirerAnother preventive asthma medicationis Montelukast (Singulair), a pill taken at night that also helps nasal stuffiness.

  • Generic drugs to save province $10M - Winnipeg Sun

    Generic drugs to save province $10MWinnipeg SunSome of the 179 newly available drugs include Abilify for schizophrenia, Actemra for rheumatoid arthritis, Januvia and Onglyza for diabetes, Xgeva for prostate cancer, generic zolmitriptan for migraine therapy, generic montelukast for asthma, .

  • Strong profit growth and Zetia patent win for Merck & Co - Pharma Times

    Strong profit growth and Zetia patent win for Merck & CoPharma TimesMerck's best-selling treatment was once again the asthma/allergic rhinitis drug Singulair (montelukast), which inched up 1% to $1.